We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

European Court of First Instance (CFI) Partly Annuls European Commission’s Decision in GlaxoSmithKline (GSK)

11 October 2006

Brussels Legal
On 27 September 2006, in a long-awaited judgment, the European Court of First Instance (CFI) partly annulled a 2001 decision of the European Commission finding that GSK’s General Sales Conditions to its wholesalers in Spain infringed Article 81(1) EC (equivalent of Section 1 of the Sherman Act) and denying GSK an exemption under Article 81(3) EC. According to the CFI, the Commission erred in considering only the short-term, price-impact issues in its analysis in EC competition law while ruling out consideration of the issues raised by GSK as to the longer-term, anti-competitive impact on innovation of parallel traders’ price arbitrage.


Loading data